Biopharmaceuticals
DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation
Published in Drug Law Weekly, April 7th, 2009
DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biopharmaceutical company, announced that it has entered into a $400,000 common stock equity investment agreement priced at market with its clinical trials management partner, Numoda Corporation (Numoda). One hundred thousand dollars of this investment will be completed in January 2010. This investment follows and enhances the collaboration between DOR and Numoda announced June 30, 2008 and represents partial payment by DOR under the collaboration agreement.
Numoda, which specializes in providing life sciences companies with innovative trial-performance metrics in enrollment, logistics,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
Source: Drug Law Weekly (2009-04-07)
More Articles from Drug Law Weekly
- Advocates for Youth
Advocates for Youth Applauds Court Ruling on EC Age Restriction - Americans United for Life (AUL)
Americans United for Life Condemns Ruling Increasing Minors' Access to Dangerous Plan B - Arcot Systems, Inc.
Arcot Digital Signature Solution Certified Compliant with SAFE-BioPharma Digital Standard™ - Bio-Tech Medical Software, Inc.
Domino/Aronberg Prescription Drug Validation Plan Saves Lives, Protects Privacy, Costs Less - Biologics
Consumer, Business and Labor Groups Endorse Bipartisan Senate Bill Authorizing Biogenerics - Biopharmaceuticals
GPhA Statement on the Introduction of the Bipartisan Senate Biogenerics Consensus Bill: 'Promoting Innovation and Access to Life-Saving Medicine Act' - More from this issue of Drug Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
